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ABSTRACT
Natural killer T (NKT) cells play a critical role in the host’s innate immune response. CD1d-mediated presentation of
glycolipid antigens to NKT cells has been established; however, the mechanisms by which NKT cells recognize infected or
cancerous cells remain unclear. 5′-AMP activated protein kinase (AMPK) is a master regulator of lipogenic pathways. We
hypothesized that activation of AMPK during infection and malignancy could alter the repertoire of antigens presented by
CD1d and serve as a danger signal to NKT cells. In this study, we examined the effect of alterations in metabolism on
CD1d-mediated antigen presentation to NKT cells and found that an infection with lymphocytic choriomeningitis virus
rapidly increased CD1d-mediated antigen presentation. Hypoxia inducible factors (HIF) enhance T-cell effector functions
during infection, therefore antigen presenting cells pretreated with pharmacological agents that inhibit glycolysis, induce
HIF and activate AMPK were assessed for their ability to induce NKT-cell responses. Pretreatment with 2-deoxyglucose,
cobalt chloride, AICAR and metformin significantly enhanced CD1d-mediated NKT-cell activation. In addition, NKT cells
preferentially respond to malignant B cells and B-cell lymphomas express HIF-1α. These data suggest that targeting cellular
metabolism may serve as a novel means of inducing innate immune responses.
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INTRODUCTION
In contrast to the MHC class I restriction that dictates clas-
sical T-cell recognition, NKT cells are CD1d restricted. The
CD1d molecule is structurally similar to MHC class I, with a
three domain α chain that associates non-covalently with β2-
microglobulin (β2m). However, unlike MHC class I, CD1d has
a hydrophobic antigen-binding groove that enables selective
binding of glycolipid antigens (East, Kennedy and Webb 2014;
Zajonc and Girardi 2015). Also, in comparison to the relatively
ubiquitous expression of MHC class I on almost all eukaryotic
cells, CD1d is expressedmainly on dendritic cells, macrophages,
B cells and T cells (Salio et al. 2014).
CD1d-mediated antigen presentation begins with the syn-
thesis of the CD1dα chain in the endoplasmic reticulum (ER)
(Barral and Brenner 2007). Here, chaperones like calnexin,
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calreticulin and Erp57 help to ensure that it is properly folded
(Kang and Cresswell 2002). The antigen-binding groove of CD1d
is occupied by a ‘self’ lipid thought to be loaded by microsomal
triglyceride transfer protein (Dougan et al. 2005). After associa-
tion with β2m, the CD1d molecule follows the secretory path-
way from the ER to the Golgi and reaches the plasmamembrane
(PM). Studies from our group and others have shown that in or-
der to present an activating endogenous antigen to NKT cells,
CD1d molecules must recycle from the PM to endocytic com-
partments, due primarily to the presence of a CD1d-localized
tyrosine-based targeting motif (Jayawardena-Wolf et al. 2001;
Chiu et al. 2002; Roberts et al. 2002) that is analogous to the invari-
ant chain (Ii) for MHC class II molecules. In fact, Ii, which medi-
ates trafficking of MHC class II from the Golgi to the lysosomes,
can also associate with CD1d; however, the tyrosine-basedmotif
is necessary for the proper recycling of CD1dmolecules and their
trafficking to endocytic compartments (Sullivan, Nagarajan and
Kronenberg 2005).
Following internalization from the PM, adaptor proteins AP2
and AP3 direct CD1d molecules back to an endocytic compart-
ment, also known as MIIC, where MHC class II molecules are
normally loaded with peptide antigens (Cernadas et al. 2003;
Elewaut et al. 2003). Once in the endocytic recycling compart-
ment, the stabilizing self-lipid is exchanged for other activat-
ing lipid antigens with the help of saposins (Kang and Cress-
well 2004; Zhou et al. 2004). These loaded CD1d molecules are
then re-expressed on the PM and can be recognized by invariant
NKT cells. This complex process of CD1d-mediated antigen pro-
cessing and presentation has several potential levels of control,
yet very few endogenous regulatory factors for this process have
been identified.
Some of the factors known to be important for CD1d-
mediated antigen processing and presentation are the mitogen-
activated protein kinases (MAPK), PKCδ and Rho kinases
(Renukaradhya et al. 2005, 2008; Brutkiewicz et al. 2007; Gallo
et al. 2012). Altered metabolism is a common feature of both
viral infections and cancers, including lymphoma (Platanias
and Vakana 2011; Levy and Bartosch 2015; Lovelace and Polyak
2015). Recently, we reported that overexpression or induction
of Bcl-xL in mouse B-cell lymphoma cells results in signifi-
cantly increased CD1d-mediated antigen presentation. In con-
trast, knockdown of Bcl-xL leads to a significant decrease in level
of the intracellular trafficking of CD1d to LAMP+ compartments
and a reduction in CD1d-mediated NKT cells activation (Subrah-
manyam, Carey and Webb 2014). These data demonstrate that
Bcl-xL functions to regulate CD1d-mediated antigen presenta-
tion by altering intracellular trafficking of CD1d and support
the notion that the regulation of intracellular CD1d-mediated
antigen presentation may serve as a strategy that can influence
host immune recognition of stressed cells. Moreover, these data
implicate a role for alterations in cellular bioenergetics in the
modulation of antigen processing and presentation. Thus, we
hypothesized that changes in metabolism due to infection or
malignancy could serve as danger signals and enhance CD1d-
mediated NKT-cell responses.
Classically, two pathways are thought to exist for NKT-cell
activation. An antigen-dependent pathway by which NKT cells
are activated through direct recognition of microbial glycolipid
antigens via their TCR (Kinjo et al. 2005, 2006; Mattner et al.
2005; Sriram et al. 2005) and another cytokine-dependent path-
way due to the ability of NKT cells to respond to innate or inflam-
matory stimuli, which may be associated with self-Ag recogni-
tion (Brigl et al. 2003; Mattner et al. 2005; Paget et al. 2007; Salio
et al. 2007; Brigl and Brenner 2010; Darmoise et al. 2010). Given
the important role that CD1d-specific NKT cells play in many
different types of infections, autoimmunity and transplantation,
we investigated NKT-cell responses during an acute viral infec-
tion and to cancer cells. These two divergent stimuli were potent
inducers of cytokine production by NKT cells, and our studies
reveal a novel role for the energy sensor AMP-activated protein
kinase (AMPK) in regulating CD1d-mediated antigen processing
and presentation.
MATERIALS AND METHODS
Peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMC) were isolated by
Ficoll-Hypaque (Amersham Pharmacia Biotek, Uppsala, Swe-
den) density gradient centrifugation. All donors gave written in-
formed consent before enrolling in the study. The Institutional
Review Board of University of Maryland School of Medicine (Bal-
timore, MD) approved this investigation. Human primary B cells
were isolated using the Pan B-cell isolation kit from StemCell
Technologies according to the manufacturer’s instructions. To
generate primary human NKT cells, PBMC were purchased from
Biological Specialty Corp and the New York Blood Center. NKT
cells were isolated and expanded as previously reported (Webb
et al. 2012).
Mice
Male and female C57BL/6 wild-type mice were obtained from
The Jackson Laboratory (Bar Harbor, ME). All mice were infected
between 6 and 12 weeks of age and were age and sex matched.
All experiments were performed in accordance with procedures
approved by Indiana University School of Medicine animal use
and care committee.
Virus and infection of mice
The Armstrong strain of lymphocytic choriomeningitis virus
(LCMV) was provided by Dr R. Welsh (University of Mas-
sachusetts Medical Center, Worcester, MA). Viral stocks were
prepared in BHK cells as previously described (Spence et al. 2001).
Mice were infected i.p. with 1–2 × 105 plaque forming units
PFU of LCMV as previously described (Hobbs et al. 2001; Roberts
et al. 2004). On the indicated days post infection (p.i.), thymi and
spleens were harvested and cocultured with NKT-cell hybrido-
mas.
Cell lines, antigens and other reagents
The Vα14+ NKT-cell hybridoma cell lines DN32.D3, N38-2C12,
N38-3C3 and the Vα5+ CD1d-specific NKT-cell hybridoma N37-
1A12 have all been described (Lantz and Bendelac 1994;
Brutkiewicz et al. 1995; Roberts et al. 2002) and were cul-
tured in IMDM medium supplemented with 5% FBS, peni-
cillin/streptomycin and 2 mM L-glutamine (Gibco Waltham,
MA). L-CD1d cells are CD1d1-transfected L cells and the con-
trols, L-vector cells were cultured in DMEM supplemented with
10% FBS, 2 mM L-glutamine, penicillin/streptomycin and 500
μg mL−1 G418 as previously reported. Human B-cell lymphoma
lines, Farage, Raji, Ramos, SU-DHL-4, SU-DHL-6 and Karpas were
generously provided by Dr Ronald Gartenhaus (University of
Maryland School of Medicine). The human B lymphoblastoid
cell line transfected with human CD1D, C1R-CD1D was gen-
erously provided by Dr Mark Exley (Harvard Medical School,
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Boston, MA). All B-cell lymphoma lines were cultured in RPMI
1640 medium supplemented with non-essential amino acids
(Sigma-Aldrich St. Louis, MO), sodium pyruvate (Gibco), vitamin
solution (Gibco), 2-mercaptoethanol (Gibco), 10% FBS and peni-
cillin/streptomycin. Pharmacological agents 2-deoxyglucose
(2DOG), cobalt chloride and metformin (all from Sigma), A-
769662 (Abcam Cambridge, MA) and AICAR (Cell Signaling Tech-
nology Danvers, MA) were used as described.
Mononuclear cell isolation
Thymi and spleens were harvested from uninfected and LCMV-
infected mice and processed into single-cell suspensions. Ery-
throcytes were lysed by hypotonic shock in 0.84% NH4Cl. The
remaining cells were washed twice with IMDM supplemented
with 5% FBS (complete medium), and then resuspended in the
same medium.
NKT cell hybridoma assay
To measure endogenous Ag presentation by CD1d1 molecules,
LCD1 cells were infected with LCMV (MOI = 5) for 20 h at 37◦C.
The cells were then washed three times in cold PBS. The NKT-
cell hybridomas (5–10 × 104 cells/well) were incubated with 5
× 105 target cells for 24 h at 37◦C. Coculture supernatants were
harvested, and IL-2 production was measured by ELISA.
Flow cytometry
Cells were stained in PBS containing 0.5% BSA and 2 mM EDTA
for 30 min at 4◦C with a PE-conjugated antibody to CD1d (clone
1B1) from BD Biosciences (San Jose, CA). Data were collected on
an LSR II from BD Biosciences (San Jose, CA) and analyzed using
FCS Express Version 3 from De Novo Software (Los Angeles, CA).
Western blotting
Cells were lysed using lysis buffer containing NaCl (150 mM),
Tris-Cl (50 mM), EDTA (8.5 mM), sodium azide (0.02%), NP-40
(0.1%) and complete mini protease inhibitor cocktail tablet from
Roche Applied Science (Indianapolis, IN) as directed by theman-
ufacturer, and prepared in water. Proteins were resolved by elec-
trophoresis on a 4%–12% gradient polyacrylamide gel and trans-
ferred to a PVDF membrane using the iBlot transfer system (Life
Technologies, Carlsbad, CA). All gels, equipment, buffers and
other materials were from Life Technologies and were used as
per the manufacturer’s instructions.
Statistical analyses
Two-tailed student’s t test, one-way analysis of variance
(ANOVA) or two-way ANOVA were used as appropriate. Specific
experimental groups were compared with controls using the
Sidak’s multiple comparisons test. P value less than 0.05 was
considered significant. All analyses were performed using Prism
5.02 by GraphPad (La Jolla, CA). # P < 0.0001, ∗∗∗ P < 0.001, ∗∗ P <
0.01 and ∗ P < 0.05.
RESULTS
LCMV infection induces NKT-cell responses
We have previously reported a dichotomy in NKT-cell responses
between different viral infections. Infection with vaccinia virus
or vesicular stomatitis virus resulted in a decrease in CD1d-
mediated NKT-cell activation, whereas an acute infection with
LCMV did not (Renukaradhya et al. 2005). To further investigate
the effects of an acute LCMV infection on CD1d-mediated anti-
gen presentation to NKT cells, LCD1 cells (murine L-cell fibrob-
lasts transfected with the cd1d1 cDNA) or murine thymocytes
were infected with LCMV for 90 min, washed and cocultured
with a panel of murine NKT-cell hybridomas. The production of
IL-2 into the supernatants was used as an indication of CD1d-
dependent NKT-cell activation. Following infection with LCMV,
there was an increase in NKT-cell activation induced by both
LCD1 cells and murine thymocytes, suggesting a virus-induced
enhancement in CD1d-mediated antigen presentation (Fig. 1A
and B). This increase in NKT-cell responses was due to CDd1-
dependent antigen presentation, because infection of control
L cells and the NKT-cell hybridomas themselves did not result
in an increase in cytokine production by NKT cells (data not
shown). Importantly, these observations were made with both
canonical (Vα14+) and non-canonical NKT cells (Vα5+).
To determinewhether infectionwith LCMV could alter CD1d-
mediated NKT cells activation in different cell types, we in-
fected the murine dendritic cell line, FSDC, and cocultured
these cells with a panel of NKT-cell hybridomas. LCMV infec-
tion of FSDC cells resulted in an increase in NKT- cell activa-
tion, without an effect on surface CD1d expression (Fig. 1C and
D). These data suggest that a viral infection can rapidly modu-
late the repertoire of endogenous antigens presented by CD1d
molecules.
We next investigated whether an acute LCMV infection
would alter CD1d-mediated antigen presentation ex vivo. There-
fore, C57BL/6 mice were infected with LCMV for the indicated
time periods; thymi were then harvested and cocultured with
NKT cells. It was found that in vivo infection with LCMV rapidly
alters CD1d-mediated antigen presentation (Fig. 2A and B). It
has been established that stimulationwith naı¨vemurine spleno-
cytes do not activate type I NKT cells (Park, Roark and Bendelac
1998); however, we found that LCMV infection confers recogni-
tion of splenocytes by NKT cells in the absence of exogenous
antigen (Fig. 2A and B).
It has been reported that cytotoxic T cells can recognize
very early, minor changes in virus-infected target cells (Jack-
son et al. 1976; Jackson, Ada and Tha Hla 1976); thus, we exam-
ined whether alterations in glycolysis (such as those induced
by a virus infection) would enhance CD1d-mediated NKT-cell
activation. Hypoxia-inducible factor (HIF) transcription factors
play an important role in the metabolic changes that drive cel-
lular adaptation to low oxygen availability. HIF expression can
be induced by hypoxia, but also by other stress-associated fac-
tors such as infections and cancer (Palazon et al. 2014). Thus,
we hypothesized that induction of HIF-1α or alterations in gly-
colytic metabolism may the mechanism by which NKT cells
are able to distinguish between healthy cells and infected or
malignant cells. To examine whether changes in metabolism
would alter CD1d-mediated NKT cells, LCD1 cells were incu-
bated with increasing doses of 2DOG, an inhibitor of cellular gly-
colysis (Zhong et al. 2009). It was found that treatment resulted
in an increase in CD1d-mediated NKT-cell activation (Fig. 3A and
B). Due to the variability in cytokine production by the NKT-
cell hybridomas, these experiments were repeated >7 times and
the trend demonstrated a reproducible increase in NKT-cell re-
sponses. Likewise, pretreatment with cobalt chloride (CoCl2),
which also induces HIF-1α and increases oxidative respiration
(Li et al. 2015), resulted in a concomitant increase in NKT-cell
activation (Fig. 3B and C). Importantly, CoCl2 pretreatment did
not alter CD1d cell surface expression at any dose examined
(Fig. 3D). Collectively, these data suggest that changes in glucose
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Figure 1. Acute infection with LCMV enhances CD1d-mediated NKT-cell responses. (A) LCD1 or (B) murine thymocytes were cultured inmedium or infected with LCMV
(MOI = 5) for 90 min, washed with PBS, then cocultured with NKT cells (DN32.D3 and N37-1A12) for 20–24 h. IL-2 was measured, as an indication of NKT-cell activation,
by standard cytokine ELISA. Data shown as % control and are the average of two experiments performed in triplicate. Data are representative of >5 independent
experiments. Cytokine release from NKT cells cocultured with uninfected cells was compared to LCMV-infected cells. ∗ P < 0.05. (C) LCMV infection increases NKT-cell
responses to FSDC. A dendritic cell line, FSDC, was infected with LCMV as described above, and cocultured with NKT-cell hybridomas. Data shown are the average of
two experiments performed in triplicate. (D) LCMV infection does not alter CD1d cell surface expression. Following 24 p.i. FSDC cells were stained for CD1d and MHC
class I expression and analyzed by flow cytometry.
Figure 2. LCMV infection rapidly increases CD1d-mediated NKT-cell activation. (A) C57BL/6 mice were infected with LCMV for the indicated time periods, thymi
were harvested and cocultured DN32.D3. IL-2 was measured, as an indication of NKT-cell activation, by standard cytokine ELISA. Data shown are the average of one
experiment performed in triplicate and is representative of two independent experiments. (B) LCMV infection confers recognition of murine splenocytes by NKT-cell
hybridomas. Splenocytes were harvested from LCMV-infected C57BL/6 mice (d3 p.i.) and cocultured with DN32.D3 NKT-cell hybridomas. Data shown are the average
of one experiment performed in triplicate and are representative of >3 independent experiments. In other experiments, splenocytes were harvested 1, 2, 3 and 8 days
p. i. and in each case were able to stimulate NKT-cell hybridomas in the absence of exogenous antigen. Cytokine release from NKT cells cocultured with uninfected
cells was compared to LCMV-infected cells. ∗∗ P < 0.01 and ∗ P < 0.05.
metabolism can alert the innate immune response, by induc-
ing CD1d-mediated NKT-cell activation. This induction is likely
due to a change in the repertoire of endogenous glycolipid anti-
gens, as there was no detectable increase in CD1d on the cell
surface.
Primary cancer cells express HIF-1α and can induce
NKT-cell activation
We have found that alterations in metabolism due to treatment
with 2DOG and cobalt chloride can enhance CD1d-mediated
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Figure 3. Pretreatment with 2DOG and cobalt chloride results in increased CD1d-dependent stimulation of NKT cells. (A) LCD1 were incubated with 2DOG or
(B and C) cobalt chloride for 4 h at 37˚C at the indicated concentrations, washed and cocultured with NKT hybridomas, DN32.D3, N38-3C3 and N37-1A12. Medium
and L cells transfected with an empty vector (Lvec) were included as negative controls. Data shown are the average of one experiment performed in triplicate and
are representative of >7 independent experiments. (B) Cumulative data from three experiments shown as % control due to the variability in cytokine production by
NKT-cell hybridomas. (D) Pretreatment with cobalt chloride does not affect CD1d cell surface expression. LCD1 were analyzed for surface expression of CD1d or MHC
class I by flow cytometry following a 4 h pretreatment with concentrations of CoCl2 indicated above (black histogram is the negative control). Net cytokine production
from NKT cells cocultured with vehicle control-treated cells (Med) was compared to drug-treated cells. # P < 0.0001, ∗∗∗ P < 0.001, ∗∗ P < 0.01 and ∗ P < 0.05.
Figure 4. B-cell lymphomas upregulate HIF-1α. (A) HIF-1α expression was assessed in a panel of B-cell lymphoma lines following 4 h treatment with CoCl2 (100 μM) or
in freshly isolated malignant B cells from a patient by western blotting. HSP86 served as a loading control. (B) Primary human NKT cells were cocultured with B cells
isolated from the peripheral blood of healthy donors (HD) or patients with lymphoma (NHL) in the absence or presence of antigen- α-GalCer (100 ng mL−1) for 48 h.
IFN-γ was measured, as an indication of human NKT-cell activation, by standard cytokine ELISA. Data shown are from one experiment of two similar experiments
performed in triplicate. Net cytokine production from NKT cells stimulated with HD B cells was compared to NHL B cells. ∗∗ P < 0.01.
NKT-cell responses; thus, we hypothesized that this may be a
mechanismbywhichNKT cells also recognize transformed cells.
Interestingly, we found that alterations in glucose metabolism,
either by inhibiting glycolysis or inducing HIF-1, resulted in en-
hanced NKT-cell activation (Fig. 3A–C). We confirmed this us-
ing a panel of human B-cell lymphoma following treatment
with CoCl2-induced HIF-1α (Fig. 4A). Moreover, and in agree-
ment with a prior study (Argyriou et al. 2011), we found that
HIF-1α was also highly expressed in malignant B cells isolated
from a patient with lymphoma (NHL B cells) (Fig. 4A). To inves-
tigate whether human NKT cells can recognize primary non-
Hodgkin’s lymphoma (NHL) cells, B cells were isolated from the
peripheral blood of healthy donors and patients with active dis-
ease.When cocultured in the presence of the NKT-cell agonist α-
galactosylceramide (α-GalCer), stimulationwith lymphoma cells
induced higher levels of IFN-γ production by human primary
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Figure 5. Induction of AMPK results in enhanced NKT-cell responses. (A) LCD1 cells were incubated with AICAR (1000 μM) for 0, 30 or 60 h at 37◦C, washe, and then
cocultured NKT-cell hybridoma lines DN32.D3, N38-3C3 and N37-1A12. Medium and L cells transfected with empty vector (Lvec) are included as negative controls.
One experiment performed in triplicate, representative of three independent experiments, is shown. (B) Levels of both p-AMPK and AMPK were found to increase in
a time-dependent fashion following treatment with AICAR. GAPDH was included as a loading control. (C) Pretreatment with AICAR increases CD1d-mediated NKT-
cell activation. C1R-CD1D B-cell lymphoblasts were pretreated with 0 or 1000 μM AICAR, A79665 or metformin in the presence or absence of 100 ng mL−1 α-GalCer
for 2 h, washed and then cocultured with primary human NKT cells. Cytokine release was measured by ELISA. Data shown are from one experiment of two similar
experiments performed in triplicate. # P < 0.0001, ∗∗∗ P < 0.001, ∗∗ P < 0.01 and ∗ P < 0.05.
NKT cells, compared to healthy B cells (Fig. 4B) (Li et al. 2014).
Collectively, these data suggest that the upregulation of HIF-1α
expression by malignant B cells may modulate CD1d-mediated
activation of NKT cells.
Induction of AMPK results in increased CD1d-mediated
antigen presentation
AMPK serves as a fuel-sensing enzyme that is activated by the
binding of AMP and subsequent phosphorylation by upstream
kinases, such as the tumor suppressor liver kinase B1 (LKB1),
when cells sense an increase in the ratio of AMP to ATP (Flavin,
Zadra and Loda 2011). Acute activation of AMPK stimulates fatty
acid oxidation to generate more ATP and simultaneously in-
hibits ATP-consuming processes, including fatty acid and pro-
tein syntheses. This preserves energy for acute cell-surviving
program; in contrast, chronic activation leads to inhibition of cell
growth. Studies have shown that AMPK is rapidly activated in
vitro by both physiological and pathophysiological low-oxygen
conditions (Grahame Hardie 2014). We sought to investigate
whether activation of AMPK would have an impact on CD1d-
mediated antigen presentation to NKT cells. CD1d express-
ing cellswere pretreatedwith 5-aminoimidazole-4-carboxamide
1-D-ribonucleoside (AICAR), the prototypical AMPK activator
and then cocultured with NKT cells. As shown in Fig. 5A,
we found that AMPK activation significantly increases CD1d-
mediated NKT cell activation. We confirmed AMPK induction
by AICAR by western blot (Fig. 5B). To confirm a role for AMPK
activation in being an important regulator of CD1d-mediated
NKT-cell responses overall (i.e. not just in murine fibroblasts),
we treated the human B lymphoblastoid cell line, C1R-CD1D,
with metformin, AICAR or another AMPK activator- A769665.
Importantly, the activation of AMPK alone induced NKT-cell
activation to levels comparable to stimulation of cells treated
with the potent NKT-cell agonist, α-GalCer (Fig. 5C). These data
demonstrate that AMPK activation significantly increases CD1d-
mediated NKT-cell activation, and further suggests that NKT
cells may be uniquely sensitive to changes in glycolytic respi-
ration, as a mechanism used by the innate immune system to
control neoplastic transformation and initiate antiviral immune
responses.
DISCUSSION
In this study, we sought to ascertain the mechanisms by which
NKT cells recognize virally infected and malignant cells. We
found that NKT cells produce higher levels of cytokine when co-
culturedwith LCMV-infected cells or primary B-cell lymphomas,
compared to healthy, uninfected control cells. IFN-γ -associated
metabolic changes have been observed during viral infection
(Wikoff et al. 2009) and during malignancy (Flavin, Zadra and
Loda 2011). Thus, we subsequently examined the effect of alter-
ations inmetabolism onCD1d-mediated Ag presentation to NKT
cells. Pretreatmentwith 2DOG, cobalt chloride andAICAR,which
block glycolysis, induce HIF-1α and activate AMPK, respectively,
resulted in an increase in CD1d-mediated NKT-cell responses.
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Figure 6. Proposedmodel illustrating themechanisms bywhich AMPK functions as a centralmetabolic switch that governs glucose and lipidmetabolism and activation
of this master switch serves as a danger signal to alert NKT cells to infection and malignancy. Once activated, AMPK reduces plasma insulin levels, suppresses ATP-
consuming metabolic functions (such as synthesis of fatty acids, sterols, glycogen and proteins) and increases ATP-producing activities (such as glucose uptake, fatty
acid oxidation andmitochondrial biogenesis) to restore energy homeostasis. In this study, antigen presenting cells were pretreated with 2DOG, cobalt chloride, AICAR,
A769662 and metformin to targeted several steps in this pathway, as indicated with red arrows, and found an enhanced CD1d-mediated NKT-cell activation. These
data suggest that targeting cellular metabolism may serve as a novel means of inducing innate immune responses.
These data suggest that targeting cellularmetabolismmay serve
as a novel means of inducing innate immune responses.
NKT cells comprise an important subset of T cells that are
activated by glycolipid antigens within the context of CD1d (Ter-
abe and Berzofsky 2014). Given their potential high therapeu-
tic significance, NKT-cell-based clinical trials have been con-
ducted in patients with advanced non-small cell lung cancers
and with head and neck cancers (reviewed in Fujii et al. 2013).
However, the mechanisms by which NKT cells discriminate be-
tween healthy normal cells and cancerous or infected cells re-
main unclear. Consequently, in our studies, we have primarily
focused our efforts on delineating the underlying mechanism(s)
by which NKT cells recognize and destroy these targets, in or-
der to make progress on the development of effective NKT-cell-
based therapeutic strategies.
In our previous study examining the role of Bcl-xL in CD1d-
mediated antigen presentation, we found that there was in-
creased levels of Rab7 after Bcl-xL knockdown compared to
the scrambled control (Subrahmanyam, Carey and Webb 2014).
These data suggest that knocking down Bcl-xL leads to upreg-
ulation of Rab7 and an expansion of the late endosomal com-
partment, acting as a depot for CD1d molecules and resulting
in impaired trafficking to the lysosomal compartment, and fur-
ther implicates a role for autophagy in regulating antigen pre-
sentation. AMPK promotes autophagy (Dong et al. 2016); thus, in
this study, we investigated the role of AMPK on CD1d-dependent
NKT-cell responses.
While other studies have examined the role of metabolism
on T-cell responses (Tamas et al. 2006; Palmer et al. 2015), we
have focused on its role in antigen processing and presentation.
Specifically, AMPK suppresses mTOR-dependent transcriptional
regulators (such as cyclin D1 andmyc) to inhibit cell growth and
tumorigenesis. Two mTORC1-regulated transcription factors in-
volved in cell growth are the sterol-regulatory element-binding
protein 1 and HIF1. The HIF subunits are stabilized through the
hypoxic inactivation of the von Hippel–Lindau E3 ligase that tar-
gets them for destruction. Conditions that lower intracellular
ATP levels; for example, low glycolytic rates from low glucose
concentrations or inhibitors, such as 2DOG, can lead to the ac-
tivation of AMPK in a LKB1-dependent manner. Importantly, we
have found that pretreatment of antigen presenting cells with
2DOG, CoCl2 and AICAR all result in increased NKT-cell activa-
tion, highlighting the importance of targeting these pathways.
Our proposed model is shown in Fig. 6.
It has been well established that tumor metabolism is sig-
nificantly different compared to normal cells and is charac-
terized by an increase in the utilization of glycolysis, even
in the presence of an adequate oxygen supply (the Warburg
8 Pathogens and Disease, 2016, Vol. 74, No. 6
Effect)(Semenza 2007). Additionally, the microenvironment sur-
rounding tumors is typically poorly vascularized and causes low
levels of oxygen near the tumor. A number of proteins, specifi-
cally HIF1-α and AMPK, are upregulated under conditions of hy-
poxia. These proteins control the transcriptional regulation of
over 100 different proteins responsible for glucose metabolism,
lipidmetabolism and a diverse set of other functions. In order to
assess the potential role of these pathways on CD1d-mediated
NKT-cell responses, we used pharmacological agents to induce
HIF and AMPK, and found that both resulted in an increase in
CD1d-dependent NKT-cell activation. Taken together, our data
suggest that stressors such as certain viral infections and can-
cers induce alter cellular bioenergetics leading to a switch in ox-
idative respiration. We believe that this alters the repertoire of
endogenous glycolipid antigens presented by CD1d molecules
to NKT cells, thereby acting as a danger signal and enhanc-
ing NKT-cell-mediated effector responses. Ongoing studies are
focused on characterizing the changes in the lipid profiles, as
well as identifying pharmacological agents that enhance CD1d-
mediated NKT-cell responses.
It has been reported that patients who are currently tak-
ing metformin, a classic activator of AMPK responsible for de-
creasing circulating glucose levels by blocking complex I of
the electron transport chain, are at a significantly decreased
risk of developing certain types of cancer (Mayer, Klotz and
Venkateswaran 2015). Because this phenomenon correlateswith
generating a hypoxic state in tumor cells, we wished to investi-
gate if similar hypoxia-inducing compounds would increase im-
munologic cell activity, specific NKT cells, in vitro. We found that
treatment of antigen presenting cells (APCs) with agents that al-
termetabolism such as, 2DOG, CoCl2, and AICAR, followed by co-
culture with NKT cells, causes an increase in NKT-cell cytokine
secretion. Additionally, we observed an increase in AMPK and
well as pAMPK transcription. Taken together, our studies impli-
cate a novel role for metabolism in enhancing the innate im-
mune response. Furthermore, we posit that activating AMPK by
repurposing FDA-approved drugs, such as metformin, has the
potential to revolutionize treatment regimens, by replacing in-
terventions that have life-threatening toxicities with ones that
are safe and effective.
ACKNOWLEDGEMENTS
The authors would like to thank the patients and healthy donors
who allowed their samples to be studied.
FUNDING
This work was supported by the National Institutes of Health
[ R21 CA162277, R21 CA199544, R21 CA184469 to T.J.W. and R01
46455 to R.R.B.].
Conflict of interest. None declared.
REFERENCES
Argyriou P, Papageorgiou SG, Panteleon V et al. Hypoxia-
inducible factors in mantle cell lymphoma: implication for
an activated mTORC1–>HIF-1alpha pathway. Ann Hematol
2011;90:315–22.
Barral DC, Brenner MB. CD1 antigen presentation: how it works.
Nat Rev Immunol 2007;7:929–41.
Brigl M, Brenner MB. How invariant natural killer T cells respond
to infection by recognizing microbial or endogenous lipid
antigens. Seminars in Immunology 2010;22:79–86.
Brigl M, Bry L, Kent SC et al.Mechanism of CD1d-restricted natu-
ral killer T cell activation during microbial infection. Nat Im-
munol 2003;4:1230–7.
Brutkiewicz RR, Bennink JR, Yewdell JW et al. TAP-independent,
b2-microglobulin-dependent surface expression of func-
tional mouse CD1.1. J Exp Med 1995;182:1913–9.
Brutkiewicz RR, Willard CA, Gillett-Heacock KK et al. Protein ki-
nase C delta is a critical regulator of CD1d-mediated antigen
presentation. Eur J Immunol 2007;37:2390–5.
CernadasM, SugitaM, van derWel N et al. Lysosomal localization
of murine CD1d mediated by AP-3 is necessary for NK T cell
development. J Immunol 2003;171:4149–55.
Chiu YH, Park SH, Benlagha K et al. Multiple defects in antigen
presentation and T cell development by mice expressing cy-
toplasmic tail-truncated CD1d. Nat Immunol 2002;3:55–60.
Darmoise A, Teneberg S, Bouzonville L et al. Lysosomal α-
Galactosidase Controls the Generation of Self Lipid Antigens
for Natural Killer T Cells. Immunity 2010;33:216–28.
Dong Z, Liang S, Hu J et al. Autophagy as a target for
hematological malignancy therapy. Blood Rev 2016,
http://dx.doi.org/10.1016/j.blre.2016.04.005.
Dougan SK, Salas A, Rava P et al.Microsomal triglyceride transfer
protein lipidation and control of CD1d on antigen-presenting
cells. J Exp Med 2005;202:529–39.
East JE, Kennedy AJ, Webb TJ. Raising the roof: the preferential
pharmacological stimulation of Th1 and th2 responses me-
diated by NKT cells. Med Res Rev 2014;34:45–76.
Elewaut D, Lawton AP, Nagarajan NA et al. The adaptor protein
AP-3 is required for CD1d-mediated antigen presentation of
glycosphingolipids and development of Valpha14i NKT cells.
J Exp Med 2003;198:1133–46.
Flavin R, Zadra G, Loda M. Metabolic alterations and targeted
therapies in prostate cancer. J Pathol 2011;223:283–94.
Fujii SI, Shimizu K, Okamoto Y et al. NKT Cells as an Ideal Anti-
Tumor Immunotherapeutic. Front Immunol 2013;4:409.
Gallo RM, Khan MA, Shi J et al. Regulation of the actin cytoskele-
ton by Rho kinase controls antigen presentation by CD1d. J
Immunol 2012;189:1689–98.
Grahame Hardie D. AMP-activated protein kinase: a key regula-
tor of energy balance with many roles in human disease. J
Intern Med 2014;276:543–59.
Hobbs JA, Cho S, Roberts TJ et al. Selective loss of natural killer
T cells by apoptosis following infection with lymphocytic
choriomeningitis virus. J Virol 2001;75:10746–54.
Jackson DC, Ada GL, Hapel AJ et al. Changes in the surface of
virus-infected cells recognized by cytotoxic T cells. II. A re-
quirement for glycoprotein synthesis in virus-infected target
cells. Scand J Immunol 1976;5:1021–9.
Jackson DC, Ada GL, Tha Hla R. Cytotoxic T cells recognize
very early, minor changes in ectromelia virus-infected target
cells. Aust J Exp Biol Med 1976;54:349–63.
Jayawardena-Wolf J, Benlagha K, Chiu YH et al. CD1d endosomal
trafficking is independently regulated by an intrinsic CD1d-
encoded tyrosine motif and by the invariant chain. Immunity
2001;15:897–908.
Kang SJ, Cresswell P. Calnexin, calreticulin, and ERp57 cooperate
in disulfide bond formation in human CD1d heavy chain. J
Biol Chem 2002;277:44838–44.
Kang SJ, Cresswell P. Saposins facilitate CD1d-restricted presen-
tation of an exogenous lipid antigen to T cells. Nat Immunol
2004;5:175–81.
Kinjo Y, Tupin E, Wu D et al. Natural killer T cells recognize di-
acylglycerol antigens from pathogenic bacteria. Nat Immunol
2006;7:978–86.
Webb et al. 9
Kinjo Y, Wu D, Kim G et al. Recognition of bacterial glycosphin-
golipids by natural killer T cells. Nature 2005;434:520–5.
Lantz O, Bendelac A. An invariant T cell receptor a chain is used
by a unique subset ofmajor histocompatibility complex class
I-specific CD4+ and CD4-8- T cells in mice and humans. J Exp
Med 1994;180:1097–106.
Levy P, Bartosch B. Metabolic reprogramming: a hallmark of viral
oncogenesis. Oncogene 2015, DOI: 10.1038/onc.2015.479.
Li G, Zhao Y, Li Y et al. Up-regulation of neuronal nitric ox-
ide synthase expression by cobalt chloride through a HIF-
1α mechanism in neuroblastoma cells. Neuromol Med 2015;
17:443–53.
Li J, SunW, Subrahmanyam PB et al.NKT Cell Responses to B Cell
Lymphoma. Med Sci 2014;2:82–97.
Lovelace E, Polyak S. Natural products as tools for
defining how cellular metabolism influences cellular im-
mune and inflammatory function during chronic infection.
Viruses 2015;7:2933.
Mattner J, Debord KL, Ismail N et al. Exogenous and endogenous
glycolipid antigens activate NKT cells duringmicrobial infec-
tions. Nature 2005;434:525–9.
Mayer MJ, Klotz LH, Venkateswaran V. Metformin and prostate
cancer stem cells: a novel therapeutic target. Prostate Cancer
P D 2015;18:303–9.
Paget C, Mallevaey T, Speak AO et al. Activation of Invariant NKT
Cells by Toll-like Receptor 9-Stimulated Dendritic Cells Re-
quires Type I Interferon and Charged Glycosphingolipids. Im-
munity 2007;27:597–609.
Palazon A, Goldrath Ananda W, Nizet V et al. HIF transcrip-
tion factors, inflammation, and immunity. Immunity 2014;
41:518–28.
Palmer CS, Ostrowski M, Balderson B et al. Glucose metabolism
regulates T cell activation, differentiation and functions.
Front Immun 2015;6:1.
Park SH, Roark JH, Bendelac A. Tissue-specific recognition of
mouse CD1 molecules. J Immunol 1998;160:3128–34.
Platanias L, Vakana E. AMPK in BCR-ABL expressing leukemias.
Regulatory effects and therapeutic implications. Oncotarget
2011;2:1322–8.
Renukaradhya GJ, Khan MA, Shaji D et al. Vesicular stomatitis
virusmatrix protein impairs CD1d-mediated antigen presen-
tation through activation of the p38 MAPK pathway. J Virol
2008;82:12535–42.
Renukaradhya GJ, Webb TJ, Khan MA et al. Virus-induced inhibi-
tion of CD1d1-mediated antigen presentation: reciprocal reg-
ulation by p38 and ERK. J Immunol 2005;175:4301–8.
Roberts TJ, Lin Y, Spence PM et al. CD1d1-dependent control of
the magnitude of an acute antiviral immune response. J Im-
munol 2004;172:3454–61.
Roberts TJ, SriramV, Spence PM et al. Recycling CD1d1molecules
present endogenous antigens processed in an endocytic
compartment to NKT cells. J Immunol 2002;168:5409–14.
SalioM, Silk JD, Jones EY et al. Biology of CD1- andMR1-restricted
T cells. Annu Rev Immunol 2014;32:323–66.
Salio M, Speak AO, Shepherd D et al.Modulation of human natu-
ral killer T cell ligands on TLR-mediated antigen-presenting
cell activation. Proceedings of the National Academy of Sciences
2007;104:20490–5.
Semenza GL. HIF-1 mediates the Warburg effect in clear cell re-
nal carcinoma. J Bioenerg Biomembr 2007;39:231–4.
Spence PM, Sriram V, Van Kaer L et al. Generation of cellular
immunity to lymphocytic choriomeningitis virus is indepen-
dent of CD1d1 expression. Immunology 2001;104:168–74.
Sriram V, Du W, Gervay-Hague J et al. Cell wall glycosphin-
golipids of Sphingomonas paucimobilis are CD1d-specific
ligands for NKT cells. Eur J Immunol 2005;35:1692–701.
Subrahmanyam PB, Carey GB, Webb TJ. Bcl-xL regulates CD1d-
mediated antigen presentation to NKT cells by altering
CD1d trafficking through the endocytic pathway. J Immunol
2014;193:2096–105.
Sullivan BA, Nagarajan NA, Kronenberg M. CD1 and MHC
II find different means to the same end. Trends Immunol
2005;26:282–8.
Tamas P, Hawley SA, Clarke RG et al. Regulation of the energy
sensor AMP-activated protein kinase by antigen receptor and
Ca2+ in T lymphocytes. J Exp Med 2006;203:1665–70.
Terabe M, Berzofsky JA. The immunoregulatory role of type I and
type II NKT cells in cancer and other diseases. Cancer Immunol
Immun 2014;63:199–213.
Webb TJ, Li X, Giuntoli RL, 2nd et al. Molecular identification of
GD3 as a suppressor of the innate immune response in ovar-
ian cancer. Cancer Res 2012;72:3744–52.
Wikoff WR, Kalisak E, Trauger S et al. Response and recovery in
the plasma metabolome tracks the acute LCMV-induced im-
mune response. J Proteome Res 2009;8:3578–87.
Zajonc DM, Girardi E. Recognition of microbial glycolipids by
Natural Killer T cells. Front Immun 2015;6:400.
Zhong D, Xiong L, Liu T et al. The glycolytic inhibitor
2-deoxyglucose activates multiple prosurvival pathways
through IGF1R. J Biol Chem 2009;284:23225–33.
Zhou D, Mattner J, Cantu C, 3rd et al. Lysosomal glycosphin-
golipid recognition by NKT cells. Science 2004;306:1786–9.
